You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HIV Envelope Protein gp120

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV Trial in Puerto Rico, United States (rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys))

Completed
  • HIV Infections
  • rgp120/HIV-1MN
  • +2 more
  • Long Beach, California
  • +33 more
Oct 27, 2021

HIV Trial in Rochester, Seattle (gp160 Vaccine (Immuno-AG), rgp120/HIV-1IIIB, rgp120/HIV-1MN)

Completed
  • HIV Infections
  • gp160 Vaccine (Immuno-AG)
  • +4 more
  • Rochester, New York
  • +1 more
Oct 28, 2021

HIV-1-infection Trial in Amsterdam (ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes)

Active, not recruiting
  • HIV-1-infection
  • ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes
  • Amsterdam, Noord-Holland, Netherlands
    Amsterdam University Medical Centers, location AMC
Jan 31, 2023

HIV Trial in Pittsburgh (rgp120/HIV-1 SF-2, Env 2-3, HIVAC-1e)

Completed
  • HIV Infections
  • rgp120/HIV-1 SF-2
  • +3 more
  • Pittsburgh, Pennsylvania
    JHU AVEG
Oct 27, 2021

Healthy Trial (763SIP8/MPLA-5 vaccine)

Not yet recruiting
  • Healthy
  • 763SIP8/MPLA-5 vaccine
  • (no location specified)
Mar 15, 2023

HIV Trial in Boston (env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant)

Active, not recruiting
  • HIV Infections
  • env (A,B,C,A/E)/gag (C) DNA Vaccine
  • +3 more
  • Boston, Massachusetts
    Brigham and Women's Hospital
Jun 8, 2022

HIV Trial in United States (MF59, rgp120/HIV-1 SF-2)

Completed
  • HIV Infections
  • MF59
  • rgp120/HIV-1 SF-2
  • Birmingham, Alabama
  • +3 more
Oct 27, 2021

HIV Trial in Saint Louis, Rochester, Seattle (Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated

Completed
  • HIV Infections
  • Aluminum hydroxide
  • +7 more
  • Saint Louis, Missouri
  • +2 more
Oct 28, 2021

HIV Trial in United States (N332-GT5 gp140 (IM, Bolus), N332-GT5 gp140 (IM, Fractioned), N332-GT5 gp140 (SC, Bolus))

Not yet recruiting
  • HIV
  • N332-GT5 gp140 (IM, Bolus)
  • +7 more
  • San Francisco, California
  • +7 more
Sep 8, 2023

HIV Trial in Saint Louis, Pittsburgh (gp160 Vaccine (MicroGeneSys))

Completed
  • HIV Infections
  • gp160 Vaccine (MicroGeneSys)
  • Saint Louis, Missouri
  • +1 more
Oct 27, 2021

HIV Trial in Boston, Seattle, Nairobi (BG505 SOSIP.664 gp140, adjuvanted, Placebo)

Active, not recruiting
  • HIV Infections
  • BG505 SOSIP.664 gp140, adjuvanted
  • Placebo
  • Boston, Massachusetts
  • +2 more
May 6, 2022

HIV Trial in United States (rgp120/HIV-1MN, rgp120/HIV-1 SF-2)

Completed
  • HIV Infections
  • rgp120/HIV-1MN
  • rgp120/HIV-1 SF-2
  • Birmingham, Alabama
  • +6 more
Oct 28, 2021

HIV, Systemic Lupus Erythematosus Trial in Durham (AIDSVAX® B/E)

Completed
Has Results
  • HIV Infections
  • Systemic Lupus Erythematosus
  • AIDSVAX® B/E
  • Durham, North Carolina
    Duke Human Vaccine Institute CRS
Jan 31, 2022

HIV, HIV Seronegativity Trial in Baltimore (Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59)

Completed
  • HIV Infections
  • HIV Seronegativity
  • Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)
  • +3 more
  • Baltimore, Maryland
    JHU AVEG
Oct 27, 2021

HIV Infection Trial in Badalona (ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).,

Recruiting
  • HIV Infection
  • ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).
  • Normal saline solution
  • Badalona, Barcelona, Spain
    Germans Trias i Pujol Hospital
Jul 11, 2022

HIV Trial in Johannesburg (CH505TF gp120, GLA-SE adjuvant, Placebo)

Recruiting
  • HIV Infections
  • CH505TF gp120
  • +2 more
  • Johannesburg, Gauteng, South Africa
    Perinatal HIV Research Unit (PHRU), Soweto CRS
Apr 29, 2022

HIV Trial in Rochester, Nashville, Seattle (HIV-1 C4-V3 Polyvalent Peptide Vaccine)

Completed
  • HIV Infections
  • HIV-1 C4-V3 Polyvalent Peptide Vaccine
  • Rochester, New York
  • +2 more
Oct 27, 2021

HIV Trial in Saint Louis (gp160 Vaccine (MicroGeneSys))

Completed
  • HIV Infections
  • gp160 Vaccine (MicroGeneSys)
  • Saint Louis, Missouri
    St. Louis Univ. School of Medicine AVEG
Oct 27, 2021

HIV Trial in United States (Aluminum hydroxide, QS-21, rgp120/HIV-1MN)

Completed
  • HIV Infections
  • Aluminum hydroxide
  • +2 more
  • Saint Louis, Missouri
  • +4 more
Oct 28, 2021

HIV Trial in Pittsburgh, Nashville (Hepatitis B Vaccine (Recombinant), gp160 Vaccine (MicroGeneSys))

Completed
  • HIV Infections
  • Hepatitis B Vaccine (Recombinant)
  • gp160 Vaccine (MicroGeneSys)
  • Pittsburgh, Pennsylvania
  • +1 more
Oct 27, 2021

HIV Trial (GEO-D02 DNA, MVA/HIV62B Vaccine, B63521^11 gp120)

Withdrawn
  • HIV Infections
  • GEO-D02 DNA
  • +4 more
  • (no location specified)
Oct 13, 2021

HIV Trial in Baltimore (ALVAC-HIV gp160MN (vCP125), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2)

Completed
  • HIV Infections
  • ALVAC-HIV gp160MN (vCP125)
  • +2 more
  • Baltimore, Maryland
    JHU AVEG
Oct 27, 2021

HIV Trial in Nashville, Seattle (HIVAC-1e, gp160 Vaccine (MicroGeneSys))

Completed
  • HIV Infections
  • HIVAC-1e
  • gp160 Vaccine (MicroGeneSys)
  • Nashville, Tennessee
  • +1 more
Oct 26, 2021

HIV Trial in Rochester (MTP-PE/MF59, Env 2-3)

Completed
  • HIV Infections
  • MTP-PE/MF59
  • Env 2-3
  • Rochester, New York
    Univ. of Rochester AVEG
Oct 27, 2021

HIV, HIV Seronegativity Trial in Rochester, Nashville, Seattle (MTP-PE/MF59, Env 2-3)

Completed
  • HIV Infections
  • HIV Seronegativity
  • MTP-PE/MF59
  • Env 2-3
  • Rochester, New York
  • +2 more
Oct 28, 2021